SynthesisFrontiers in nutrition2025
The effect of omega-3 supplementation on metabolic, inflammatory and oxidative stress biomarkers in pregnant women: a systematic review and meta-analysis.
Synthesis in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This meta-analysis evaluates the effects of omega-3 supplementation on metabolic, inflammatory, and oxidative stress in pregnancy women by synthesizing findings from randomized controlled trials (RCTs), as existing evidence remains inconclusive. Methods: A systematic search was conducted using PubMed, Scopus, and Web of Science until July 2024. Random-effects models were applied to estimate each outcome's standardized mean difference (SMD) and 95% confidence intervals (CI). Results: A total of 14 studies were included in the meta-analysis. The duration of omega-3 supplementation ranged from 6 to 29 weeks. Omega-3 supplementation did not have a significant effect on FBS (SMD = -0.74, 95% CI: -1.94, 0.45), and insulin (SMD = -0.76, 95% CI: -1.77, 0.24), TC (SMD = 0.11, 95% CI: -0.20, 0.42), and LDL-C (SMD = 0.32, 95% CI: -0.17, 0.81), IL-6 (SMD = 2.12, 95% CI: -0.56, 4.80), MDA (SMD = -1.67, 95% CI: -3.39, 0.05), and TAC (SMD = 2.59, 95% CI: -0.37, 5.54). However, triglyceride (SMD = -0.96, 95% CI: -1.77, -0.16) and CRP (SMD = -0.98, 95% CI: -1.86, -0.11) significantly decreased, and HDL-C cholesterol levels significantly increased (SMD = 0.72, 95% CI: 0.21, 1.22) following omega-3 supplementation. Conclusion: This study suggests omega-3 supplementation may improve lipid profiles and reduce inflammatory biomarkers during pregnancy. However, the presence of heterogeneity across trials highlights the need for further well-conducted studies. Thus, findings should be interpreted with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.